Intraoperative hyperthermic intraperitoneal chemotherapy as adjuvant chemotherapy for advanced gastric cancer patients with serosal invasion  by Kang, Lung-Yun et al.
Available online at www.sciencedirect.comJournal of the Chinese Medical Association 76 (2013) 425e431
www.jcma-online.comOriginal Article
Intraoperative hyperthermic intraperitoneal chemotherapy as adjuvant
chemotherapy for advanced gastric cancer patients with serosal invasion
Lung-Yun Kang, King-Tong Mok, Shiuh-Inn Liu, Cheng-Chong Tsai, Being-Whey Wang,
I-Shu Chen, Yu-Chia Chen, Bo-Min Chang, Nan-Hua Chou*
Division of General Surgery, Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ROC
Received July 9, 2012; accepted November 24, 2012AbstractBackground: To evaluate hyperthermic intraperitoneal chemotherapy (HIPEC) as an adjuvant chemotherapy in advanced gastric cancer (AGC)
patients with serosal invasion.
Methods: Patients who received radical surgery and palliative surgery between January 2002 and December 2010 were retrospectively examined.
Patients were divided into two groups, namely, one group that underwent surgery and another group that underwent surgery with HIPEC. All
patients who received HIPEC had suspected serosal invasion on an abdominal computed tomography or by the surgeon’s assessment during the
operation.
Results: The prophylactic groups included 83 patients who underwent gastrectomy alone. A total of 29 patients underwent gastrectomy with
HIPEC. The 5-year survival rates were 10.7% and 43.9%, respectively. The 5-year mean survival times were 22.66 (17.55e25.78) and 34.81
(24.97e44.66) months ( p ¼ 0.029), respectively. There were 52 patients who had a recurrence of carcinomatosis among 133 patients who had
resections (52/133, 39.1%). The 3-year disease-free survival rate for carcinomatosis was 28.87% in the group that received surgery alone,
whereas it was 66.03% in the group that received HIPEC. There was no significant difference in the rate of complication between the two groups
in the prophylactic group ( p ¼ 0.542). Thus, curative surgery with HIPEC had a better prognosis for AGC with serosal invasion. The carci-
nomatosis recurrence time was longer in patients who underwent gastrectomy with HIPEC and received R0 resection.
Conclusion: The survival benefit of HIPEC as an adjuvant therapy for gastric cancer patients with serosal invasion should be validated in a large
cohort.
Copyright  2013 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Gastric cancer is one of the most frequent causes of cancer-
related mortality worldwide.1 The most favorable treatment is
curative surgery and adjuvant chemotherapy.2 However, the
prognosis is poor after tumor recurrence. Typically, peritoneal
carcinomatosis (PC) is the main recurrent form of gastric
cancer. Previous research has suggested that cytoreductive* Corresponding author. Dr. Nan-Hua Chou, Division of General Surgery,
Department of Surgery, Kaohsiung Veterans General Hospital, 386, Ta-Chung
1st Road, Kaohsiung 813, Taiwan, ROC.
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http://dx.doi.org/10.1016/j.jcma.2013.04.004surgery with hyperthermic intraperitoneal chemotherapy
(HIPEC) can be an effective treatment option for PC in many
intra-abdominal cancers.3
However, other reports have shown HIPEC to be effective
in preventing PC,4e8 and can extend the time before peritoneal
recurrence. HIPEC is still not a standard adjuvant therapy for
advanced gastric cancer (AGC) because of the timing of drug
delivery and the choice of drug. Although there are more
complications associated with HIPEC, its safety and efficacy
has been well proven in other studies.
We therefore reviewed records for patients in our hospital
who had AGC with serosal invasion to demonstrate the effi-
cacy and safety of HIPEC.hinese Medical Association. All rights reserved.
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Patients who received radical surgery and palliative surgery
between January 2002 and December 2010 were included in
this study. However, those patients without serosal invasion in
their pathologic report were excluded. Patients were divided
into two groups, namely, group A (included patients who
underwent surgery) and group B (included patients who un-
derwent surgery with HIPEC). The two groups were divided
further into two subgroups based on the objective of prophy-
laxis (group C and group G) and therapeutic treatment (group
D and group H).
The prophylaxis group excluded palliative surgeries, stump
cancer, and distant metastases. The patients in the
gastrectomy-only group were designated as group C, and the
gastrectomy with HIPEC patients were noted as group D.
The therapeutic group included patients who underwent
palliative surgery without or with HIPEC, which emphasized
the therapeutic effect of HIPEC. In the therapeutic groups
(group G and H), group G was the surgery-only group and
group H included patients who underwent surgery with
HIPEC. None of the patients received peritonectomies, but
rather palliative gastrectomy combined with other resections
without peritonectomy in the therapeutic groups.
The PC recurrence refers to patients, initially without PC
grossly, who received curative surgery that was followed by
PC recurrence. Another episode of PC recurrence was limited
in patients and was noted as resected in the postoperative
pathology report. The patients were divided into two groups,
namely, the surgery-only group (group E) and the surgery with
HIPEC group (group F). Some of the patients had distant
metastases and lymph node metastasis. For all affected pa-
tients, the duration of carcinomatosis was calculated.
A preoperative survey was arranged for patients in this
study. In some cases, endoscopy was performed to proveFig. 1. Patient groups. Group E is the surgery-only group in PCgastric cancer. In addition, abdominal computed tomography
(CT) and chest radiography were performed. All patients who
received HIPEC had suspected serosal invasion on abdominal
CT or by the surgeon’s assessment during the operation, and
PC recurrence was assessed by CT. We applied Cox multi-
variate analysis to control for confounding factors.2.1. ProcedureHIPEC was performed after gastrectomy and lymph node
dissection, and before closure of the abdominal cavity. One
inflow tube was placed in a Douglas pouch, following which
the skin of the abdomen was attached to a retractor ring, and a
plastic sheet covered the open wound to keep the temperature
stable. Approximately 3e4 L of lactated Ringer solution
containing cisplatin (30 mg/L), mitomycin (10 mg/L), and
etoposide (20 mg/L) was circulated for 60 minutes. The
temperature was maintained at 41e43C. After HIPEC, the
wound was closed.
Statistical analyses were performed using SPSS (version
12.0; SPSS Inc., Chicago, IL, USA). Between-group com-
parisons of clinical data were performed using independent
sample t tests, and postoperative survival curves were gener-
ated according to the KaplaneMeier method and compared
using the log-rank test. Independent prognostic factors were
analyzed with a Cox proportional hazards regression method.
Statistical significance was assessed for p < 0.05.
Informed content was obtained from all patients before
operation. The study complied with institutional review board
protocols.
3. Results
A total of 172 patients were included in the study (Fig. 1).
Of these, 121 patients received surgery alone (group A).patients. Group F is the surgery with HIPEC in PC group.
Fig. 2. Survival curves in the prophylactic group for advanced gastric cancer
with serosal invasion ( p ¼ 0.029). HIPEC ¼ hyperthermic intraperitoneal
chemotherapy.
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designated as group G. Seven patients were excluded due to
stump cancer.
Fifty-one patients underwent resection with HIPEC (group
B; Table 1). Twenty-nine patients were in group D, and 16
patients were deemed as group H. Six patients were excluded
due to stump cancer (three patients) and recurrence from
previous gastric cancer (three patients).
The prophylaxis group excluded palliative surgeries, stump
cancer, and distant metastases. There were 83 patients in the
gastrectomy-only group (group C). The gastrectomy with
HIPEC group comprised 29 patients (group D). The 5-year
survival rate was 10.7% in group C and 43.9% in group D.
The 5-year mean survival times were 21.66 (range:
17.55e25.78 months) and 34.81 months (range: 24.97e44.66
months), respectively ( p ¼ 0.029; Fig. 2).
The survival analysis for gastric cancer is shown in Table 2.
The T-stage and HIPEC procedure were independent prog-
nostic factors.
A total of 52 patients (44 in group A and eight in group B)
had a recurrence of carcinomatosis out of 133 patients who
had resections (52/133; 39.1%), including 99 patients in group
A and 34 patients in group B. The 3-year disease-free survival
rate for carcinomatosis recurrence was 28.87% in the surgery-
only group (group E) and 66.03% in the surgery with HIPEC
group (group F). The mean recurrence time of PC was 20.55
months (range: 17.62e23.47 months) in the surgery-only
group and 27.29 months (range: 22.30e32.39 months) in the
group that received surgery with HIPEC ( p ¼ 0.0451; Table 3;
Fig. 3). The only factor leading to a significant difference was
HIPEC. Combined resection did not influence recurrence.
In the therapeutic group, 31 patients comprised the surgery-
only group (group G) and 16 patients underwent surgery withTable 1
Comparison of data between hyperthermic intraperitoneal chemotherapy and contr
Gastrectomy (n ¼ 12
Age 66.36 (14.54)
Gender, M/F 85/36 (70%/30%)
Location
U/M/L/U þ M or M þ L/U þ M þ L/S 20/18/59/13/4/7
Size 6.59 (3.85)
Histological diagnosis
Well/intermediately versus
Poorly/undifferentiated
25/96 (21%/79%)
T stage, 4A/4B 90/31 (74%/26%)
LN stage, 0/1/2/3 12/21/25/63
Distant metastasis, M0/M1 110/11 (91%/9%)
Carcinomatosis, P0 versus P1 95/26 (78%/22%)
Stage, 2B/3A/3B/3C/4 8/13/15/45/40
Gastrectomy, Sub./Tot. 53/68 (44%/56%)
LND, D1/D2/D3 5/112/4
Combined resection
With/without 27/84 (22%/78%)
Residual tumor
R0/R1or R2 83/38 (69%/31%)
Perioperative mortality 12 (10%)
Complication 23 (19%)
Chemotherapy 25 (21%)
HIPEC ¼ hyperthermic intraperitoneal chemotherapy; LN ¼ lymph node; LND ¼HIPEC (group H). The mean survival time was 8.04 months
(range: 6.14e9.93 months) in the surgery-only group and
14.63 months (range: 2.70e26.57 months) in patients who
underwent surgery with HIPEC ( p ¼ 0.486).ol patients.
1) Gastrectomy þ HIPEC (n ¼ 51) p
64.00 (15.20) 0.339
34/17 (67%/33%) 0.645
8/8/18/10/4/3 0.278
6.38 (3.77) 0.747
13/38 (25%/75%) 0.595
38/13 (75%/25%) 0.559
7/6/11/27 0.836
42/9 (82%/18%) 0.111
34/17 (67%/33%) 0.132
6/1/10/17/17 0.897
21/30 (41%/59%) 0.753
3/48/0 0.227
24/27 (47%/53%) 0.001
30/21 (59%/41%) 0.181
7 (14%) 0.155
17 (33%) <0.001
11 (22%) 0.981
lymph node dissection.
Table 2
Survival analysis in the prophylactic group.
Variables p (Univariate) p (Multivariate)
Age, 65 versus <65 0.742 d
Gender, M/F 0.115 d
Size, 6 cm versus <6 cm 0.805 d
Lymph node metastasis, yes versus no 0.114 d
HIPEC, yes versus no 0.032 0.043
T stage, 4B versus 4A 0.003 0.005
Chemotherapy, yes versus no 0.434 d
Complication, yes versus no 0.855 d
Histology
Well/intermediately versus
Poorly/undifferentiated
0.888 d
Gastrectomy, total versus partial 0.323 d
Combine resection, yes versus no 0.305 d
HIPEC ¼ hyperthermic intraperitoneal chemotherapy.
Fig. 3. Three-year disease-free survival rate for carcinomatosis recurrence
( p ¼ 0.0451). HIPEC ¼ hyperthermic intraperitoneal chemotherapy.
428 L.-Y. Kang et al. / Journal of the Chinese Medical Association 76 (2013) 425e431During study period, a total of 58 patients received the
HIPEC procedure for prophylactic purposes during the oper-
ation, including all T stages of gastric cancer: two patients
were designated as T2, 27 patients were T3, and only 29 pa-
tients (group D) had genuine serosal invasion (T4a or T4b) in
their pathology report. The rate of accuracy of clinical im-
pressions of serosal invasion was 50%.
Among the patients treated by surgery, resection was
considered curative by the operating surgeon in 29 of 51 pa-
tients (56.9%) in the HIPEC group, compared with 83 of 121
patients (68.6%) in the surgery-only group ( p ¼ 0.018).
The most common complications were intra-abdominal
abscesses, pulmonary complications, and anastomosis leak-
ages (Table 4). The total number of operative mortalities were
12 (10%) in group A and seven in group B (15%; p ¼ 0.155).
Additional complications were discovered in cases involving
operative mortality. There was no significant difference in the
rate of complications between the two prophylactic groups
( p ¼ 0.542), though there was a significant difference between
the therapeutic groups ( p ¼ 0.023).
More lymph node-positive patients had abnormal preoper-
ative serum carcinoembryonic antigen (CEA) and carbohy-
drate antigen (CA) 19-9 levels compared with lymph node-
negative patients (CEA: 40%/14%, p < 0.001; CA 19-9:
27%/11%, p ¼ 0.01).Table 3
Univariate analysis for disease-free survival in the peritoneal carcinomatosis
group.
Variables Risk ratio 95% CI p
Age, 65 versus <65 0.841 0.485e1.459 0.538
Gender, M/F 0.852 0.486e1.492 0.575
Size, 6 cm versus < 6 cm 1.185 0.657e2.137 0.573
Lymph node metastasis, yes versus no 1.351 0.608e3.001 0.460
HIPEC, yes versus no 0.445 0.209e0.947 0.036
T stage, 4B versus 4A 1.804 0.956e3.403 0.068
Chemotherapy, yes versus no 1.380 0.751e2.538 0.300
Complication, yes versus no 0.875 0.411e1.864 0.729
Combine resection, yes versus no 0.930 0.494e1.751 0.823
CI ¼ confidence interval; HIPEC ¼ hyperthermic intraperitoneal
chemotherapy.Thirty-seven patients (21.5%) received systemic chemo-
therapy in our study. There was no significant difference
( p ¼ 0.434).
Cytology of ascites was performed in 15 patients who
received HIPEC. The cytology results of three patients were
positive, of which two patients (66.67%) had PC, whereas the
results were negative for the remaining 12 patients, of which
two (17%) patients had PC. Of the 10 patients who were
cytology negative without PC, PC recurred in four of them
(40%). The sole patient who was cytology positive without PC
had no PC recurrence.
4. Discussion
It had been reported in several other reports that radical
gastrectomy with HIPEC is effective for prophylaxis.4e11
There are two possible sources of PC: serosal invasion in-
creases the chance of tumor seeding to the peritoneal cavity,
and surgical trauma also spreads tumor cells to the peritoneal
cavity while lymph node dissection is performed. Marutsuka
et al reported that free cancer cells were found in the lavageTable 4
Complications in all patients.
Gastrectomy
(n ¼ 121)
Gastrectomy þ HIPEC
(n ¼ 51)
p
Complication 23 (19%) 17 (33%) <0.001
Intra-abdominal abscess 6 (5%) 13 (25%) <0.001
Anastomosis leakage 3 (2.5%) 6 (11.8%) <0.001
Pulmonary complication 7 (5.7%) 7 (13.7%) 0.001
HIPEC ¼ hyperthermic intraperitoneal chemotherapy.
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tients with submucosal and muscularis propria tumors,
respectively.12e15 Adjuvant chemotherapy was required for
these patients with AGC, and HIPEC is one such choice.
HIPEC can eradicate the spread of tumor cells in the perito-
neal cavity.15 Extensive intraoperative peritoneal lavage, fol-
lowed by intraperitoneal chemotherapy, had a significantly
lower incidence of peritoneal recurrence than intraperitoneal
chemotherapy alone.16
PC was the most common recurrent form of gastric cancer
after curative surgery17,18; in our study, 39.1% patients expe-
rienced peritoneal recurrence. It has been demonstrated that
HIPEC can decrease the rate of peritoneal recurrence.4e8,19
Decreasing peritoneal recurrence and delaying the time until
peritoneal recurrence can lead to longer patient survival. In our
study, the 3-year disease-free survival rate for PC recurrence
was elevated after surgery with HIPEC. In the prophylaxis
group, the HIPEC group had a better survival rate, consistent
with other studies.4e8 In the multivariate survival analysis,
HIPEC and T stage were the two factors that affected survival,
and multivariate analysis showed significant differences
resulting from both factors. Thus, HIPEC is an independent
prognostic factor in the prophylactic group and it can be
effectively used as an adjuvant chemotherapy.
There are many effective drugs for chemotherapy, such as
oxaliplatin,20 paclitaxel,21 and docetaxel.22 In our study, we
used a drug mixture of cisplatin,6,23 mitomycin C,24 and eto-
poside,25 which has been reported to be effective.
Preoperative staging can be performed using many
methods, such as positron emission tomography-CT, abdom-
inal CT, laparoscopic staging, and tumor markers. If PC was
suspected, cytoreductive surgery should be considered before
HIPEC. Laparoscopic staging is a useful tool for the diagnosis
of PC.26,27 Once PC was discovered, HIPEC was performed
with cytoreductive surgery therapeutically.
In our opinion, HIPEC is effective as prophylactic therapy,
and palliative surgery with HIPEC is not useful because of
insufficient tumor resection, which is supported by our research
data. Many reports have revealed that cytoreductive surgery
plus HIPEC is effective for AGC.28e30 The effect of HIPEC is
limited to a depth of less than 3 mm, and PC has a barrier that
can protect tumor cells from the antitoxic agents. Therefore, its
therapeutic effect for PC is limited. No peritonectomy surgery
was performed in our patients. Thus, the outcomes in our
therapeutic cohort were not different between the two groups.
Abdominal CT was used to determine clinical stage. This
method has been reported to have moderate accuracy.31,32
Many other factors were discussed for predicting serosal in-
vasion, including elevated neutrophil-to-lymphocyte ratio,
decreased hemoglobin (Hb), and poorly differentiated histol-
ogy.33 Abnormal preoperative serum tumor markers, such as
CEA and CA 19-9, were found in patients who had positive
lymph nodes (CEA: p ¼ 0.029; CA 19-9: p ¼ 0.218), but were
not related to the recurrence of carcinomatosis and carcino-
matosis.34 Tumor markers cannot be an indicator for the per-
formance of HIPEC. The sensitivity and specificity of positive
peritoneal washing cytology in predicting peritoneal recurrencewere 61% and 100%, respectively.35 The sensitivity and
specificity of positive peritoneal washing cytology for pre-
dicting peritoneal seeding were 52% and 89.6%, respectively.
In our study, the sensitivity and specificity of positive cytology
for predicting peritoneal seeding were 50% and 90.9%,
respectively. Cytology had high specificity for predicting PC.16
Positive cytology without PC could be used an indicator
for HIPEC if the false-negative rate can be improved.36 We
therefore used abdominal CT and the surgeon’s assessment to
predict serosal invasion and perform HIPEC. Consequently,
reduced accuracy was a limitation. Only 50% of patients truly
had serosal invasion, as demonstrated by pathological study
results. Kuramoto et al reported that 59% (35/59) of patients
who received intraperitoneal chemotherapy had serosal inva-
sion.16 Yu et al reported 80% accuracy for predicting serosal
invasion.37 The accuracy of predicting serosal invasion is low.
However, preoperative CT and the surgeon’s assessment during
surgery are now an indicator for HIPEC. More tools, such as
laparoscopic staging, endoscopic ultrasonography, intraperito-
neal washing cytology, and intraoperative frozen section re-
ports, are available.38e41 Cytology and intraoperative frozen
section reports may help to ascertain which patients should
receive adjuvant HIPEC.
Hyperthermia can potentiate cytostatic effects. The phar-
macological basis for using heat to supplement chemotherapy
effects is related to the increased penetration of chemothera-
peutic agents into tumors with hyperthermia, the delayed
clearance of chemotherapeutic agents from the peritoneal
cavity after direct instillation, and an increased cytotoxicity
that has been documented with selected chemotherapy
agents.37,42e44 However, the effects of heat and drug toxicity
may lead to more complications. The most common compli-
cations were anastomotic leakage, intra-abdominal abscess,
and wound infection (Table 4). There were more complications
in the HIPEC group, particularly intra-abdominal abscesses, as
seen in other studies.37,43 The rate of complication of anasto-
mosis leakage was higher in the HIPEC group. Pulmonary
complications are related to fluid overload and inflammatory
status; HIPEC can induce dehydration that shifts fluid to the
third space, and fluid supply is important. However, fluid
overload and the inflammatory process can induce pulmonary
edema and acute respiratory distress syndrome. HIPEC may
maximize this effect in the peritoneal cavity and minimize the
systemic effect.7,19,25,45 No neutropenia was noted in our study.
Operative mortality was higher in the HIPEC group, but no
significant difference between groups was found. Operative
mortality refers to death within 30 days of the operation, or
within the same admission. In the prophylactic group, there
was no significant difference in complications between the two
groups. The highest rate of complications was found in the
therapeutic group that received HIPEC. The overall condition
of patients in this group was relatively poor, and HIPEC can
impose a massive systemic stress that results in more compli-
cations and mortality. However, HIPEC for prophylaxis was
relatively safe and efficacious.
Our patient group was older, with a mean age of 65.66
(14.77) years. Notwithstanding this elevated age
430 L.-Y. Kang et al. / Journal of the Chinese Medical Association 76 (2013) 425e431representation, HIPEC still appeared to be safe for older pa-
tients. Curative surgery with HIPEC had a better prognosis for
AGC with serosal invasion. The duration before carcinoma-
tosis recurrence was longer in patients who received gastrec-
tomy with HIPEC and R0 resection, even though HIPEC was
accompanied by more complications. The survival benefit of
this strategy as an adjuvant therapy for gastric cancer patients
with serosal invasion should be validated by prospective
clinical trials in a large cohort.
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